A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL) Meeting Abstract
| Authors: | Furman, R. R.; Sharman, J. P.; Coutre, S. E.; Cheson, B. D.; Pagel, J. M.; Hillmen, P.; Barrientos, J. C.; Zelenetz, A. D.; Kipps, T. J.; Flinn, I.; Ghia, P.; Eradat, H.; Ervin, T.; Lamanna, N.; Hallek, M.; Coiffier, B.; Pettitt, A. R.; Ma, S.; Stilgenbauer, S.; Cramer, P.; Aiello, M.; Johnson, D. M.; Miller, L. L.; Li, D.; Jahn, T. M.; Dansey, R. D.; O'Brien, S. M. |
| Abstract Title: | A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL) |
| Meeting Title: | 55th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 122 |
| Issue: | 21 |
| Meeting Dates: | 2013 Dec 7-10 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2013-11-15 |
| Language: | English |
| ACCESSION: | WOS:000331385000007 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V122.21.LBA-6.LBA-6 |
| Notes: | Meeting Abstract: LBA-6 -- 55th Annual Meeting of the American-Society-of-Hematology -- DEC 07-10, 2013 -- New Orleans, LA -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
